

First Hit☐ Generate Collection

L5: Entry 1 of 1

File: DWPI

Jul 30, 1998

DERWENT-ACC-NO: 1998-427951

DERWENT-WEEK: 200008

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: New isolated LAGE-1 tumour associated nucleic acids - used to develop products for the diagnosis and treatment of LAGE-1 associated disorders, particularly tumours

INVENTOR: BOON-FALLEUR, T; DE SMET, C ; GODELAINE, D ; LETHE, B ; LUCAS, S ; LETHIE, B

PRIORITY-DATA: 1997US-0791495 (January 27, 1997)

Search Selected

Search ALL

Clear

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<input type="checkbox"/> WO 9832855 A1	July 30, 1998	E	073	C12N015/12
<input type="checkbox"/> EP 970206 A1	January 12, 2000	E	000	C12N015/12
<input type="checkbox"/> US 5811519 A	September 22, 1998		000	C07K001/00
<input type="checkbox"/> ZA 9800656 A	October 28, 1998		071	C12N000/00
<input type="checkbox"/> AU 9860421 A	August 18, 1998		000	C12N015/12

INT-CL (IPC): A61 K 38/17; A61 K 48/00; C07 K 1/00; C07 K 14/00; C07 K 14/705; C07 K 16/18; C07 K 17/00; C12 N 0/00; C12 N 15/11; C12 N 15/12; C12 Q 1/68

ABSTRACTED-PUB-NO: US 5811519A

## BASIC-ABSTRACT:

An isolated LAGE-1 tumor associated polypeptide (TAP) encoding nucleic acid molecule (I) comprises: (a) a NAM which hybridises under stringent conditions to a molecule having a nucleotide sequence (NS) selected from the 1002 or 755 bp sequences given in the specification; (b) NAMs that differ from the NAM as in (a) in codon sequence due to the degeneracy of the genetic code; and (c) complements of (a) and (b) where the isolated NAM excludes NAMs having a NS of another 755 bp sequence given in the specification (encoding a NY-ESO-1 polypeptide see US08725182)).

Also claimed are:

(1) an isolated nucleic acid molecule (NAM) selected from: (a) a unique fragment of nucleotides 1-993 of the 1002 bp sequence between 12 and 992 in length (sic); (b) a unique fragment of nucleotides 1-746 of the 755 bp sequence (as in (a) above) between 12 and 745 nucleotides in length (sic); (c) complements of the sequence as in (1, a); and (d) complements of the sequence as in (1, b) where the unique fragment excludes NAMs which consist only of fragments of the 755 bp sequence (as in (b) above);

- (2) an expression vector comprising (I) or an isolated NAM as in (1) operably linked to a promoter;
- (3) a host cell transformed or transfected with an expression vector as in (2);
- (4) an isolated polypeptide encoded by (I);
- (5) an isolated LAGE-1 polypeptide comprising aas 89-93 of the 180 aa sequence given in the specification (representing a variant of a LAGE-1 polypeptide);
- (6) an isolated LAGE-1b polypeptide comprising an aa sequence selected from aas 142-148, aas 187-205, or aas 164-179 of the 210 aa sequence given in the specification (representing a variant of a LAGE-1b polypeptide);
- (7) an isolated polypeptide selected from: (a) unique fragments of the 210 aa sequence between 9 and 209 aas in length; (b) unique fragments of 180 aa sequence between 9 and 179 aas in length, where the unique fragment excludes polypeptides consisting of fragments of another 180 aa sequence given in the specification (representing a variant of a LAGE-1 polypeptide);
- (8) an isolated polypeptide which selectively binds a protein encoded by (I);
- (9) a method for treating a subject with a disorder characterised by expression of a LAGE-1 NAM or an expression product, comprising administering to the subject autologous cytolytic T cells to ameliorate the disorder, where the cytolytic T cells are specific for complexes of an HLA molecule and a LAGE-1 TAP or an immunogenic fragment;
- (10) a method for treating a subject with a disorder characterised by expression of a LAGE-1 NAM or an expression product, comprising administering a LAGE-1 TAP or an immunogenic fragment to ameliorate the disorder;
- (11) a method for selectively enriching a population of T cells with cytolytic T cells specific for a LAGE-1 TAP comprising contacting an isolated population of T cells with an agent presenting a complex of a LAGE TAP or an immunogenic fragment and a HLA presenting molecule to selectively enrich the isolated population of T cells with the cytolytic T cells;
- (12) an isolated NAM which encodes a polypeptide as in (6) or (7).

USE - The methods and products can be used for the diagnosis and treatment of LAGE-1 associated disorders, particularly tumours.

ABSTRACTED-PUB-NO:

WO 9832855A EQUIVALENT-ABSTRACTS:

An isolated LAGE-1 tumor associated polypeptide (TAP) encoding nucleic acid molecule (I) comprises: (a) a NAM which hybridises under stringent conditions to a molecule having a nucleotide sequence (NS) selected from the 1002 or 755 bp sequences given in the specification; (b) NAMs that differ from the NAM as in (a) in codon sequence due to the degeneracy of the genetic code; and (c) complements of (a) and (b) where the isolated NAM excludes NAMs having a NS of another 755 bp sequence given in the specification (encoding a NY-ESO-1 polypeptide see US08725182)).

Also claimed are:

- (1) an isolated nucleic acid molecule (NAM) selected from: (a) a unique fragment of nucleotides 1-993 of the 1002 bp sequence between 12 and 992 in length (sic); (b) a unique fragment of nucleotides 1-746 of the 755 bp sequence (as in (a) above) between 12 and 745 nucleotides in length (sic); (c) complements of the sequence as

in (1, a); and (d) complements of the sequence as in (1, b) where the unique fragment excludes NAMs which consist only of fragments of the 755 bp sequence (as in (b) above);

(2) an expression vector comprising (I) or an isolated NAM as in (1) operably linked to a promoter;

(3) a host cell transformed or transfected with an expression vector as in (2);

(4) an isolated polypeptide encoded by (I);

(5) an isolated LAGE-1 polypeptide comprising aas 89-93 of the 180 aa sequence given in the specification (representing a variant of a LAGE-1 polypeptide);

(6) an isolated LAGE-1b polypeptide comprising an aa sequence selected from aas 142-148, aas 187-205, or aas 164-179 of the 210 aa sequence given in the specification (representing a variant of a LAGE-1b polypeptide);

(7) an isolated polypeptide selected from: (a) unique fragments of the 210 aa sequence between 9 and 209 aas in length; (b) unique fragments of 180 aa sequence between 9 and 179 aas in length, where the unique fragment excludes polypeptides consisting of fragments of another 180 aa sequence given in the specification (representing a variant of a LAGE-1 polypeptide);

(8) an isolated polypeptide which selectively binds a protein encoded by (I);

(9) a method for treating a subject with a disorder characterised by expression of a LAGE-1 NAM or an expression product, comprising administering to the subject autologous cytolytic T cells to ameliorate the disorder, where the cytolytic T cells are specific for complexes of an HLA molecule and a LAGE-1 TAP or an immunogenic fragment;

(10) a method for treating a subject with a disorder characterised by expression of a LAGE-1 NAM or an expression product, comprising administering a LAGE-1 TAP or an immunogenic fragment to ameliorate the disorder;

(11) a method for selectively enriching a population of T cells with cytolytic T cells specific for a LAGE-1 TAP comprising contacting an isolated population of T cells with an agent presenting a complex of a LAGE TAP or an immunogenic fragment and a HLA presenting molecule to selectively enrich the isolated population of T cells with the cytolytic T cells;

(12) an isolated NAM which encodes a polypeptide as in (6) or (7).

USE - The methods and products can be used for the diagnosis and treatment of LAGE-1 associated disorders, particularly tumours.

First Hit**End of Result Set**

Generate Collection

Print

L5: Entry 1 of 1

File: DWPI

Jul 30, 1998

DERWENT-ACC-NO: 1998-427951

DERWENT-WEEK: 200008

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: New isolated LAGE-1 tumour associated nucleic acids - used to develop products for the diagnosis and treatment of LAGE-1 associated disorders, particularly tumours

PF Application Serial Number (1):1998WO-US01445PF Application Serial Number (3):1998WO-US01445